PATENT CLAIM ANALYSIS

Application Number: 16065397
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "387000"]

Abstract:
Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Claim (Index 87):
The method of  claim 83  or  84 , wherein the administration is conducted simultaneously or serially with a second therapeutic treatment.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.34783
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12666423', '15122863', '14061616', '16472185', '13897927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.819217518233065
- 35 USC 102 Novelty (BERT): 0.534881330865422
- Combined Prediction Score: 0.7907838994963007
- Mean Citation Score: 367.118278
- Max Citation Score: 369.48654
- Similarity Product: 210.1391798236513

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test